Terms: = Endocrine gland cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
74 results:
1. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
2. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
3. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
[TBL] [Abstract] [Full Text] [Related]
4. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Shi YH; Xu QC; Zhu YQ; Liu ZD; Zhao GY; Liu Q; Wang XY; Wang JQ; Xu X; Su Q; Lai JM; Huang CS; Yin XY
Mol Ther; 2023 Feb; 31(2):503-516. PubMed ID: 36384875
[TBL] [Abstract] [Full Text] [Related]
5. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
[TBL] [Abstract] [Full Text] [Related]
6. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid cancer.
Iesato A; Nucera C
Adv Exp Med Biol; 2021; 1329():253-269. PubMed ID: 34664244
[TBL] [Abstract] [Full Text] [Related]
7. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract] [Full Text] [Related]
8. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract] [Full Text] [Related]
9. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Lee JM; Annunziata CM; Hays JL; Cao L; Choyke P; Yu M; An D; Turkbey IB; Minasian LM; Steinberg SM; Chen H; Wright J; Kohn EC
Gynecol Oncol; 2020 Oct; 159(1):88-94. PubMed ID: 32747013
[TBL] [Abstract] [Full Text] [Related]
10. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
[TBL] [Abstract] [Full Text] [Related]
11. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract] [Full Text] [Related]
13. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract] [Full Text] [Related]
14. Melatonin Synergizes with Sorafenib to Suppress Pancreatic cancer via Melatonin Receptor and pdgfr-β/STAT3 Pathway.
Fang Z; Jung KH; Yan HH; Kim SJ; Rumman M; Park JH; Han B; Lee JE; Kang YW; Lim JH; Hong SS
Cell Physiol Biochem; 2018; 47(5):1751-1768. PubMed ID: 29953970
[TBL] [Abstract] [Full Text] [Related]
15. Masitinib in treatment of pancreatic cancer.
Waheed A; Purvey S; Saif MW
Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
[TBL] [Abstract] [Full Text] [Related]
16. Lenvatinib in the Therapy of Aggressive Thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
[TBL] [Abstract] [Full Text] [Related]
18. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
[TBL] [Abstract] [Full Text] [Related]
19. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract] [Full Text] [Related]
20. Cotargeting of MEK and pdgfr/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract] [Full Text] [Related]
[Next]